EATRIS SERVICES

EATRIS is a gateway to the high-end expertise and resources of over 70 academic institutions across Europe. Each is committed to sharing its scientific knowledge and facilities to improve translational medicine and drug development productivity.

We offer the entire spectrum of high-end research infrastructure and patient cohorts, all accessible through just one portal.

- A translational focus which maximises product potential, providing support from discovery to clinical trial (Phase I / IIa). Throughout, you benefit from the insights of experienced professionals.

- Access to the latest discoveries and technologies, including molecular and hybrid imaging, and biomarker discovery and development, along with the key opinion leaders that drive innovation.

- Access to the highest quality facilities, with all partners having proven track records in collaborative translational research.

- Access to large and diverse patient groups.

- Central point of access via EATRIS Coordination and Support office, use of standardised frameworks and uniform policies.
From discovery to therapy
EATRIS offers a new collaboration model. Via just one doorway, EATRIS Coordination and Support provides access to the entire pipeline of academic translational infrastructure and knowhow. It optimises your route from discovery to proof of concept with a unique range of expertise in an extensive partnership of academic translational centres. In doing so, it de-fragments the biomedical expertise scattered across Europe, making a new and powerful resource available to large and small companies, charities, research institutions and governments.

Matching expertise
EATRIS greatly improves your project’s ‘scientific firepower’ by tailoring it very precisely to sources of expertise, technology, and patients. With over 70 top academic institutions to choose from, EATRIS can assemble the vital components needed to give the project momentum. At the same time, we bring in vital expertise from areas such as regulatory compliance, product development, and intellectual property management to ensure the reliability of every step. EATRIS also provides rapid access to patient cohorts and our contact with patient groups ensures that their opinions can be introduced into projects from the beginning.

Reducing risk
EATRIS institutions use cutting-edge translational technologies to speed up the accrual of knowledge about your product. Comprehensive project planning and execution, together with rigorous milestone monitoring, further ensures that resources are maximised and risks are better understood. This effective approach to translational research encourages the confidence of funders.

"Currently, translational research in novel biological targets is too advanced to be heavily funded by science ministries, too early for health ministries, too risky for industry and too complex for academia. EATRIS aims to harness the scientific knowledge of Europe’s top academic researchers so that we can help speed up the translation of new discoveries about diseases and their causes into clinical applications, especially those aimed at unmet medical needs."

"Improved understanding of the complexity of diseases and their underlying processes has resulted in the need for more personalized approaches to treating diseases. This requires diagnostics to identify a subpopulation of patients that is likely to benefit from a particular treatment. EATRIS is developing a pan-European networked approach to validate biomarkers for disease subgroups and contribute to patient stratification in clinical trials and for improved patient treatment."

"New categories of diagnostics and therapeutics have made the development environment more complex than ever, making it increasingly difficult for any one organisation to meet the demands of every aspect, whether it be academic, regulatory, intellectual property protection, project management, or contractual inputs. EATRIS has the connections, infrastructure, experience and insight to match the best resources to the need."
The early stages of drug and diagnostics development are characterised by high risk and high attrition rates. The so-called ‘valley of death’ between basic research and clinical application is at least partly related to the growing complexity of R&D. This reflects the intensity of effort required to understand disease processes and the mechanisms of drug action as well as the requirements for high quality standards (GLP, GMP, and GCP). A multi-disciplinary approach in these early stages is vital.

EATRIS offers a new development pathway
Since it is not realistic for one company to ‘know everything’, some of the expertise required for faster biomedical product development will reside beyond your organisation. The challenge is knowing where additional useful knowledge and resources may lie, since they are scattered across many different scientific communities and countries.

EATRIS has created an entirely new way of assembling expertise to overcome this fragmentation. It has created active multi-lateral partnerships with over 70 leading academic institutions across Europe, each renowned for its individual skills and high-end research facilities. Never before has such a vast range of biomedical science been made available through just one gateway.

For each project, EATRIS Coordination and Support in Amsterdam acts as a project mediator, matching your needs to our partners’ expertise. It is an original and powerful framework for improving efficiencies in development.

This fast-acting, one-entry-point ability to customise resources is all the more important as the complexity of drug development increases. The EATRIS model can achieve better productivity, reducing timelines and costs, increasing flexibility and making it easier to initiate projects.

EATRIS academic institutions provide cutting-edge infrastructure in the critical first phases of translational development. Using our single entry point, you can access comprehensive resources to help reach first-in-human application and clinical proof-of-concept in our five interrelated, highly specialised product areas:

- Advanced Therapy Medicinal Products (ATMP)
- Biomarkers
- Imaging and Tracing
- Small Molecules
- Vaccines

EATRIS gives you access to clinical specialists and patient cohorts, intellectual property expertise, regulatory strategy, and manufacturing scale-up advice.
INTEGRATING THE BEST SERVICES INTO YOUR PROJECT

EATRIS delivers uniformly high standards of expertise along the entire translational phase.

**EATRIS provides direct access to Europe's foremost academic and clinical researchers using state-of-the-art technologies**

We have more than 70 EATRIS institutions, each able to contribute their depth of knowledge, inspired thinking, and the best facilities to take insights from the earliest development stages to clinical proof of concept.

**EATRIS ensures projects have pre-determined decision gates**

As part of our ‘reducing risk’ ethos and determination to improve R&D productivity, our project advice includes clearly defined ‘go/no go’ parameters according to individual requirements.

**EATRIS guides towards regulatory compliance**

We have expert advice which sits alongside our development of R&D projects. Some of the most important is provided by embedding regulatory experts into project teams so that effective regulatory strategy is built in from the start.

**EATRIS facilitates a translational mindset**

With a clear end-product in mind, EATRIS projects keep the clinical setting clearly in view. With bi-directional input between clinicians and patients and the research laboratories, we can help anticipate further unmet medical needs.

**EATRIS offers access to large and diverse patient groups**

Working with academic clinical institutions throughout Europe, EATRIS can quickly access a wide range of patient profiles. Again, our contact with patient advocacy groups provides a functional mechanism for truly effective bi-directional communication from bench to bedside and vice versa.

**EATRIS granted ERIC status by the EU**

An ERIC is a specific European legal form to facilitate cross-border research through the joint establishment and operation of research infrastructures of European interest. This new legal framework will provide a legal personality recognised in all Member States. The benefit to EATRIS stakeholders will be the establishment of a legal framework under which cross border collaboration can take place with the aim of expediting the sharing of expertise and the faster and more efficient development of new drugs and therapies.
EATRIS PROJECT INITIATION

Four major components make up the planning and delivery of a project. They are summarised in the diagram below.

1. **Translation Assessment**
   - Review if project fits with EATRIS mission.

2. **Matchmaking**
   - Relevant disease knowledge, patient groups, high-end facilities and experts identified from EATRIS database.

3. **Exploration**
   - Assembly of project team with institutions you selected, project plan created.

4. **Initiation**
   - Definition of steps, milestones and budgets, contractual agreements.

---

1. Review of project including confirmation of unmet medical need, clear end product, innovative character and IP clarity.

2. Identification from our database of all strands of expert knowledge and facilities required including patient cohorts. Interaction and liaison with key opinion leaders and clinical specialists.

3. The design of a multi-disciplinary Project Plan, including reverse planning, milestones and budget.

4. Based on our existing partnerships with standardised frameworks and uniform policies, transaction times are greatly reduced. Bilateral contracts are made between you and the EATRIS institution. The project is executed by one or more EATRIS institutions.

Creation of optimal regulatory strategy which includes EMA Scientific Advice preparation and follow-up, clinical trial document preparation, application procedure handling and deadline monitoring.
THE PARTNERSHIP INCLUDES EUROPE’S FOREMOST CENTRES OF BIOMEDICAL SCIENCE

EATRIS partner institutions are amongst the very best in the world. By joining us as partners they commit to offering their scientific knowledge and facilities to others who wish to see them used to improve R&D productivity.

From selected academic services complementing your existing development plan, up to designing and conducting full translational development projects, EATRIS is prepared to meet your needs.

EATRIS partner institutions provide:

- Cutting-edge academic translational technology with extensive scientific and clinical expertise across Europe
- Knowhow and experience in product development, regulatory affairs, project management and intellectual property management
- Access to large and diverse patient groups

Our partner institutions are matched exactly to the needs of a project. All the introductions and the arrangement of project agreements are made by the Coordination and Support office of EATRIS in Amsterdam.

More information about EATRIS academic partners can be found at our website, www.eatris.eu.
There are well-identified areas of innovation which provide outstanding opportunities for medical product development. EATRIS has chosen five of these as the basis for making rapid impact on the process and on the emergence of novel treatments.

The five product platforms are:

- Advanced Therapy Medicinal Products
- Biomarkers
- Imaging and Tracing
- Small Molecules
- Vaccines

Each of these is the subject of a separate brochure which may be requested or downloaded from our website at www.eatris.eu.

EATRIS is a gateway to the high-end expertise and resources of over 70 academic institutions, each committed to sharing their scientific knowledge and facilities to improve translational research and drug development productivity.

Economic assessments are applied to all projects but financial imperatives are not the only focus of our work. Improvement in clinical outcomes and the development of affordable medicines, including those for neglected or orphan diseases and unmet medical needs, are our top priorities.

EATRIS will be of significant value to the following kinds of organisations:

- Pharmaceutical or biotechnology companies and SME’s having promising projects but requiring additional momentum. Typically looking for the validation of drug targets, better prediction of drug efficacy, or access to clinical expertise and patients
- Charities having impressive research portfolios with fundamental research that require translation to adoptable patient treatment outcomes
- National research funding organisations seeking to demonstrate outcomes of national budget allocations to fundamental research
- Academic institutions requiring assistance with regulatory compliance and production expertise according to GMP conditions

If you would like to discuss in confidence any aspect of EATRIS services, please call our product management team on +31 20 444 1146 or email info@eatris.eu.

Against a backdrop of tremendous progress in biomedical research, accompanied by a paradoxically low output of novel therapeutic agents, a number of European Union member countries and leading research centres came together in 2008 to create EATRIS.

Based on the principle of defragmenting the widely scattered expertise required for translational research, EATRIS focuses on creating a robust, sustainable and successful framework for the development of new preventive, diagnostic or therapeutic products.

EATRIS is staffed by a small team of professionals who run the core EATRIS function of Coordination and Support from Amsterdam. The Amsterdam office is in constant communication with our partners in academic research institutions across Europe and provides a central contact point for our client organisations.

EATRIS is governed by the participating member states represented in the Board of Governors. Every member state appoints a national scientific director, responsible for scientific coordination in their country. These national scientific directors work together in the EATRIS Board of National Directors.
SUPPORING YOU FROM DISCOVERY TO THERAPY MATCHING EXPERTISE REDUCING RISK

EATRIS
European Infrastructure for Translational Medicine

Coordination and Support Office
VU University medical center (VUmc)
De Boelelaan 1118
1081 HZ Amsterdam
The Netherlands
www.eatris.eu

CONTACT US
Phone: +31 20 444 1146
Email: info@eatris.eu